Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01906944 · ClinicalTrials.gov registry record · Phase 2
Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT01906944: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01906944 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01906944, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy for these patients.
Interventions
- DRUG Triamcinolone
- DRUG Bupivacaine 0.25%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2012-01 |
| Est. Completion | 2019-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01906944
The ClinicalTrials.gov registry entry for NCT01906944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone is the first listed.
NCT01906944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01906944 about?
NCT01906944 is a clinical study titled "Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain". Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy fo...
What is the current status of trial NCT01906944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2012-01. Estimated completion is 2019-08-18.
What interventions are being tested in trial NCT01906944?
The interventions under investigation include: Triamcinolone (DRUG), Bupivacaine 0.25% (DRUG).
Who is sponsoring clinical trial NCT01906944?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.